Radioembolization for the treatment of hepatocellular carcinoma
Author:
Open Access
- 25 June 2017
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 23 (2) , 109-114
Abstract
Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass and resin microspheres with different physical characteristics. All patients undergoing TARE must be assessed with clinical examination and laboratory tests as well as a thorough angiographic evaluation. TARE is safe and effective in the treatment of unresectable HCC, as it has longer time-to-progression, greater ability to downsize tumors for liver transplantation, less post-embolization syndrome, and shorter hospitalization compared with chemoembolization. TARE can also serve as an alternative to ablation, surgical resection, portal vein embolization, and sorafenib. The utility of TARE continues to expand with new insights in interventional oncology.Keywords
This publication has 24 references indexed in Scilit:
- Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising conceptEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Efficacy and Safety of Transarterial Radioembolization Versus Chemoembolization in Patients With Hepatocellular CarcinomaCardioVascular and Interventional Radiology, 2012
- Radiotherapy Plus Transarterial Chemoembolization for Hepatocellular Carcinoma Invading the Portal Vein: Long-Term Patient OutcomesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan CriteriaAnnals of Surgery, 2010
- Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term SurvivalHepatology, 2010
- Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term OutcomesGastroenterology, 2010
- A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus RadioembolizationAmerican Journal of Transplantation, 2009
- Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver MalignanciesJournal of Vascular and Interventional Radiology, 2006
- Quality of life in patients diagnosed with primary hepatocellular carcinoma: Hepatic arterial infusion of Cisplatin versus 90‐Yttrium microspheres (Therasphere®)Psycho-Oncology, 2003